Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: A systematic review with metaanalysis

Qian Li, Ping Zhan, Dongmei Yuan, Tangfeng Lv, Alexander Sasha Krupnick, Antonio Passaro, Alessandro Brunelli, Matthew P. Smeltzer, Raymond U. Osarogiagbon, Yong Song

Research output: Contribution to journalArticle

Abstract

Background: Non-small cell lung cancer (NSCLC) patients with N1 disease have variable outcomes, and additional prognostic factors are needed. The number of positive lymph nodes (LNs) has been proposed as a prognostic indicator. However, the number of positive LNs depends on the number of LNs examined from the resection specimen. The lymph node ratio (LNR) can circumvent this limitation. The purpose of this study is to evaluate LNR as a predictor of survival and recurrence in patients with pathologic N1 NSCLC. Methods: We systematically reviewed studies published before March 17, 2016, on the prognostic value of LNR in patients with pathologic N1 NSCLC. The hazard ratios (HRs) and their 95% confidence intervals (CIs) were used to combine the data. We also evaluated heterogeneity and publication bias. Results: Five studies published between 2010 and 2014 were eligible for this systematic review with metaanalysis. The total number of patients included was 6,130 ranging from 75 to 4,004 patients per study. The combined HR for all eligible studies evaluating the overall survival (OS) and disease-free survival (DFS) of N1 LNR in patients with pathologic N1 NSCLC was 1.53 (95% CI: 1.22-1.85) and 1.64 (95% CI: 1.19-2.09), respectively. We found no heterogeneity and publication bias between the reports. Conclusions: LNR is a worthy predictor of survival and cancer recurrence in patients with pathological N1 NSCLC.

Original languageEnglish
Pages (from-to)258-264
Number of pages7
JournalTranslational Lung Cancer Research
Volume5
Issue number3
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Lymph Nodes
Publication Bias
Confidence Intervals
Survival
Recurrence
Disease-Free Survival
Neoplasms

Keywords

  • Lymph node ratio (LNR)
  • Meta-analysis
  • N1 node
  • Non-small cell lung cancer (NSCLC)

ASJC Scopus subject areas

  • Oncology

Cite this

Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer : A systematic review with metaanalysis. / Li, Qian; Zhan, Ping; Yuan, Dongmei; Lv, Tangfeng; Krupnick, Alexander Sasha; Passaro, Antonio; Brunelli, Alessandro; Smeltzer, Matthew P.; Osarogiagbon, Raymond U.; Song, Yong.

In: Translational Lung Cancer Research, Vol. 5, No. 3, 01.06.2016, p. 258-264.

Research output: Contribution to journalArticle

Li, Qian ; Zhan, Ping ; Yuan, Dongmei ; Lv, Tangfeng ; Krupnick, Alexander Sasha ; Passaro, Antonio ; Brunelli, Alessandro ; Smeltzer, Matthew P. ; Osarogiagbon, Raymond U. ; Song, Yong. / Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer : A systematic review with metaanalysis. In: Translational Lung Cancer Research. 2016 ; Vol. 5, No. 3. pp. 258-264.
@article{ab5e15739b7247fea310cec1a1198c07,
title = "Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: A systematic review with metaanalysis",
abstract = "Background: Non-small cell lung cancer (NSCLC) patients with N1 disease have variable outcomes, and additional prognostic factors are needed. The number of positive lymph nodes (LNs) has been proposed as a prognostic indicator. However, the number of positive LNs depends on the number of LNs examined from the resection specimen. The lymph node ratio (LNR) can circumvent this limitation. The purpose of this study is to evaluate LNR as a predictor of survival and recurrence in patients with pathologic N1 NSCLC. Methods: We systematically reviewed studies published before March 17, 2016, on the prognostic value of LNR in patients with pathologic N1 NSCLC. The hazard ratios (HRs) and their 95{\%} confidence intervals (CIs) were used to combine the data. We also evaluated heterogeneity and publication bias. Results: Five studies published between 2010 and 2014 were eligible for this systematic review with metaanalysis. The total number of patients included was 6,130 ranging from 75 to 4,004 patients per study. The combined HR for all eligible studies evaluating the overall survival (OS) and disease-free survival (DFS) of N1 LNR in patients with pathologic N1 NSCLC was 1.53 (95{\%} CI: 1.22-1.85) and 1.64 (95{\%} CI: 1.19-2.09), respectively. We found no heterogeneity and publication bias between the reports. Conclusions: LNR is a worthy predictor of survival and cancer recurrence in patients with pathological N1 NSCLC.",
keywords = "Lymph node ratio (LNR), Meta-analysis, N1 node, Non-small cell lung cancer (NSCLC)",
author = "Qian Li and Ping Zhan and Dongmei Yuan and Tangfeng Lv and Krupnick, {Alexander Sasha} and Antonio Passaro and Alessandro Brunelli and Smeltzer, {Matthew P.} and Osarogiagbon, {Raymond U.} and Yong Song",
year = "2016",
month = "6",
day = "1",
doi = "10.21037/tlcr.2016.06.13",
language = "English",
volume = "5",
pages = "258--264",
journal = "Translational Lung Cancer Research",
issn = "2226-4477",
publisher = "Society for Translational Medicine (STM)",
number = "3",

}

TY - JOUR

T1 - Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer

T2 - A systematic review with metaanalysis

AU - Li, Qian

AU - Zhan, Ping

AU - Yuan, Dongmei

AU - Lv, Tangfeng

AU - Krupnick, Alexander Sasha

AU - Passaro, Antonio

AU - Brunelli, Alessandro

AU - Smeltzer, Matthew P.

AU - Osarogiagbon, Raymond U.

AU - Song, Yong

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Background: Non-small cell lung cancer (NSCLC) patients with N1 disease have variable outcomes, and additional prognostic factors are needed. The number of positive lymph nodes (LNs) has been proposed as a prognostic indicator. However, the number of positive LNs depends on the number of LNs examined from the resection specimen. The lymph node ratio (LNR) can circumvent this limitation. The purpose of this study is to evaluate LNR as a predictor of survival and recurrence in patients with pathologic N1 NSCLC. Methods: We systematically reviewed studies published before March 17, 2016, on the prognostic value of LNR in patients with pathologic N1 NSCLC. The hazard ratios (HRs) and their 95% confidence intervals (CIs) were used to combine the data. We also evaluated heterogeneity and publication bias. Results: Five studies published between 2010 and 2014 were eligible for this systematic review with metaanalysis. The total number of patients included was 6,130 ranging from 75 to 4,004 patients per study. The combined HR for all eligible studies evaluating the overall survival (OS) and disease-free survival (DFS) of N1 LNR in patients with pathologic N1 NSCLC was 1.53 (95% CI: 1.22-1.85) and 1.64 (95% CI: 1.19-2.09), respectively. We found no heterogeneity and publication bias between the reports. Conclusions: LNR is a worthy predictor of survival and cancer recurrence in patients with pathological N1 NSCLC.

AB - Background: Non-small cell lung cancer (NSCLC) patients with N1 disease have variable outcomes, and additional prognostic factors are needed. The number of positive lymph nodes (LNs) has been proposed as a prognostic indicator. However, the number of positive LNs depends on the number of LNs examined from the resection specimen. The lymph node ratio (LNR) can circumvent this limitation. The purpose of this study is to evaluate LNR as a predictor of survival and recurrence in patients with pathologic N1 NSCLC. Methods: We systematically reviewed studies published before March 17, 2016, on the prognostic value of LNR in patients with pathologic N1 NSCLC. The hazard ratios (HRs) and their 95% confidence intervals (CIs) were used to combine the data. We also evaluated heterogeneity and publication bias. Results: Five studies published between 2010 and 2014 were eligible for this systematic review with metaanalysis. The total number of patients included was 6,130 ranging from 75 to 4,004 patients per study. The combined HR for all eligible studies evaluating the overall survival (OS) and disease-free survival (DFS) of N1 LNR in patients with pathologic N1 NSCLC was 1.53 (95% CI: 1.22-1.85) and 1.64 (95% CI: 1.19-2.09), respectively. We found no heterogeneity and publication bias between the reports. Conclusions: LNR is a worthy predictor of survival and cancer recurrence in patients with pathological N1 NSCLC.

KW - Lymph node ratio (LNR)

KW - Meta-analysis

KW - N1 node

KW - Non-small cell lung cancer (NSCLC)

UR - http://www.scopus.com/inward/record.url?scp=84977539040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977539040&partnerID=8YFLogxK

U2 - 10.21037/tlcr.2016.06.13

DO - 10.21037/tlcr.2016.06.13

M3 - Article

AN - SCOPUS:84977539040

VL - 5

SP - 258

EP - 264

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

SN - 2226-4477

IS - 3

ER -